NASDAQ:ACST - Acasti Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.88 +0.02 (+2.33 %) (As of 05/20/2019 04:00 PM ET)Previous Close$0.8551Today's Range$0.8611 - $0.905652-Week Range$0.43 - $1.80Volume85,627 shsAverage Volume231,708 shsMarket Capitalization$68.75 millionP/E RatioN/ADividend YieldN/ABeta1.13 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Receive ACST News and Ratings via Email Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACST Previous Symbol CUSIPN/A CIK1444192 Webwww.acastipharma.com Phone45-0687-2262Debt Debt-to-Equity Ratio0.06 Current Ratio3.45 Quick Ratio3.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book3.52Profitability EPS (Most Recent Fiscal Year)($0.76) Net Income$-16,770,000.00 Net MarginsN/A Return on Equity-556.76% Return on Assets-135.17%Miscellaneous EmployeesN/A Outstanding Shares78,130,000Market Cap$68.75 million Next Earnings DateN/A OptionableNot Optionable Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions What is Acasti Pharma's stock symbol? Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST." How were Acasti Pharma's earnings last quarter? Acasti Pharma Inc (NASDAQ:ACST) announced its quarterly earnings data on Tuesday, January, 15th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. View Acasti Pharma's Earnings History. Has Acasti Pharma been receiving favorable news coverage? News headlines about ACST stock have trended somewhat negative on Monday, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Acasti Pharma earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. Who are some of Acasti Pharma's key competitors? Some companies that are related to Acasti Pharma include PhaseBio Pharmaceuticals (PHAS), TapImmune (MRKR), Protagonist Therapeutics (PTGX), Concert Pharmaceuticals (CNCE), Aduro BioTech (ADRO), Xenon Pharmaceuticals (XENE), Evelo Biosciences (EVLO), Aratana Therapeutics (PETX), MannKind (MNKD), Lannett (LCI), MEI Pharma (MEIP), Aclaris Therapeutics (ACRS), Minerva Neurosciences (NERV), Kamada (KMDA) and AcelRx Pharmaceuticals (ACRX). What other stocks do shareholders of Acasti Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Abraxas Petroleum (AXAS), Seanergy Maritime (SHIP), Northern Oil & Gas (NOG), Synergy Pharmaceuticals (SGYP), AcelRx Pharmaceuticals (ACRX), BIOLINERX LTD/S (BLRX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VAALCO Energy (EGY) and Actinium Pharmaceuticals (ATNM). Who are Acasti Pharma's key executives? Acasti Pharma's management team includes the folowing people: Ms. Janelle D' Alvise, Pres, CEO & DirectorDr. Pierre Lemieux, Co-Founder and Chief Operating & Scientific OfficerMr. Jean-François Boily, VP of Fin.Mr. Brian James Groch, Chief Commercial Officer (Age 52) Who are Acasti Pharma's major shareholders? Acasti Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.03%). View Institutional Ownership Trends for Acasti Pharma. Which major investors are buying Acasti Pharma stock? ACST stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Acasti Pharma. How do I buy shares of Acasti Pharma? Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Acasti Pharma's stock price today? One share of ACST stock can currently be purchased for approximately $0.88. How big of a company is Acasti Pharma? Acasti Pharma has a market capitalization of $68.75 million. The biopharmaceutical company earns $-16,770,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. What is Acasti Pharma's official website? The official website for Acasti Pharma is http://www.acastipharma.com. How can I contact Acasti Pharma? Acasti Pharma's mailing address is 545 Promenade du Centropolis Suite 100, Laval A8, H7T 0A3. The biopharmaceutical company can be reached via phone at 45-0687-2262 or via email at [email protected] MarketBeat Community Rating for Acasti Pharma (NASDAQ ACST)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 193 (Vote Outperform)Underperform Votes: 178 (Vote Underperform)Total Votes: 371MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe ACST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Roth IRA Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.